Nobuhiro Nakazawa, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stomach Neoplasms | 25 | 2024 | 1471 | 6.910 |
Why?
|
Gastrectomy | 10 | 2024 | 694 | 2.000 |
Why?
|
Esophageal Neoplasms | 15 | 2024 | 1661 | 1.550 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2024 | 9373 | 1.010 |
Why?
|
Transforming Growth Factor beta1 | 2 | 2019 | 637 | 1.000 |
Why?
|
Stromal Cells | 2 | 2019 | 1329 | 0.890 |
Why?
|
Prognosis | 27 | 2024 | 29922 | 0.790 |
Why?
|
Gastrointestinal Motility | 2 | 2021 | 235 | 0.790 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 9 | 2024 | 11868 | 0.790 |
Why?
|
Esophagectomy | 8 | 2024 | 477 | 0.770 |
Why?
|
Serum Albumin | 3 | 2021 | 675 | 0.770 |
Why?
|
Fluorouracil | 5 | 2024 | 1648 | 0.760 |
Why?
|
Oxonic Acid | 1 | 2021 | 31 | 0.760 |
Why?
|
Tegafur | 1 | 2021 | 39 | 0.760 |
Why?
|
Large Neutral Amino Acid-Transporter 1 | 1 | 2021 | 15 | 0.750 |
Why?
|
Gastrointestinal Hormones | 1 | 2021 | 101 | 0.710 |
Why?
|
L-Lactate Dehydrogenase | 1 | 2021 | 412 | 0.680 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2023 | 1106 | 0.670 |
Why?
|
Drug Resistance, Neoplasm | 3 | 2024 | 5337 | 0.640 |
Why?
|
Hyperthyroidism | 1 | 2021 | 294 | 0.630 |
Why?
|
Thyroid Hormones | 1 | 2021 | 410 | 0.590 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2021 | 647 | 0.570 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2024 | 3537 | 0.560 |
Why?
|
Hypothyroidism | 1 | 2021 | 667 | 0.510 |
Why?
|
Lectins, C-Type | 1 | 2019 | 592 | 0.510 |
Why?
|
Lipopolysaccharides | 1 | 2023 | 2216 | 0.500 |
Why?
|
Neutrophils | 4 | 2023 | 3776 | 0.480 |
Why?
|
Anastomotic Leak | 3 | 2024 | 170 | 0.410 |
Why?
|
Retrospective Studies | 30 | 2024 | 81514 | 0.410 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2019 | 4044 | 0.370 |
Why?
|
Survival Rate | 7 | 2024 | 12795 | 0.370 |
Why?
|
Lymphocytes | 4 | 2023 | 2599 | 0.370 |
Why?
|
Neutropenia | 2 | 2024 | 893 | 0.290 |
Why?
|
CD8-Positive T-Lymphocytes | 2 | 2020 | 4642 | 0.270 |
Why?
|
Lung Neoplasms | 3 | 2019 | 13451 | 0.270 |
Why?
|
TOR Serine-Threonine Kinases | 3 | 2023 | 2056 | 0.240 |
Why?
|
Hypogastric Plexus | 1 | 2024 | 16 | 0.230 |
Why?
|
Psoas Muscles | 2 | 2023 | 66 | 0.230 |
Why?
|
Humans | 50 | 2024 | 765968 | 0.230 |
Why?
|
Liver Neoplasms | 2 | 2023 | 4353 | 0.220 |
Why?
|
Vascular Fistula | 1 | 2024 | 50 | 0.220 |
Why?
|
Esophageal Fistula | 1 | 2024 | 59 | 0.220 |
Why?
|
Aged | 23 | 2024 | 171117 | 0.220 |
Why?
|
Elastin | 1 | 2024 | 299 | 0.210 |
Why?
|
Micropore Filters | 1 | 2002 | 23 | 0.210 |
Why?
|
Membrane Proteins | 1 | 2019 | 7851 | 0.200 |
Why?
|
Organoplatinum Compounds | 1 | 2024 | 404 | 0.200 |
Why?
|
Disease-Free Survival | 3 | 2024 | 6832 | 0.200 |
Why?
|
Bystander Effect | 1 | 2022 | 90 | 0.190 |
Why?
|
Pneumoperitoneum | 1 | 2022 | 46 | 0.190 |
Why?
|
Cisplatin | 3 | 2024 | 1658 | 0.190 |
Why?
|
Laparoscopy | 3 | 2024 | 2039 | 0.190 |
Why?
|
Drug Contamination | 1 | 2002 | 152 | 0.190 |
Why?
|
Submucous Plexus | 1 | 2020 | 5 | 0.180 |
Why?
|
Lymphatic Metastasis | 3 | 2024 | 2887 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2019 | 5389 | 0.180 |
Why?
|
Peristalsis | 1 | 2020 | 60 | 0.180 |
Why?
|
Thermography | 1 | 2021 | 62 | 0.180 |
Why?
|
Tooth Loss | 1 | 2022 | 198 | 0.170 |
Why?
|
Anastomosis, Roux-en-Y | 1 | 2020 | 86 | 0.170 |
Why?
|
Albumins | 1 | 2023 | 577 | 0.170 |
Why?
|
Endotoxins | 1 | 2002 | 516 | 0.170 |
Why?
|
Middle Aged | 21 | 2024 | 223009 | 0.170 |
Why?
|
Colorectal Neoplasms | 3 | 2024 | 6942 | 0.170 |
Why?
|
Orosomucoid | 1 | 2019 | 47 | 0.170 |
Why?
|
Tomography, Emission-Computed | 1 | 2002 | 1006 | 0.170 |
Why?
|
Male | 26 | 2024 | 363698 | 0.160 |
Why?
|
Phosphorylation | 2 | 2021 | 8278 | 0.160 |
Why?
|
Ghrelin | 1 | 2021 | 255 | 0.160 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2021 | 428 | 0.160 |
Why?
|
Dogs | 2 | 2021 | 3822 | 0.160 |
Why?
|
Periodontal Diseases | 1 | 2022 | 453 | 0.150 |
Why?
|
Female | 24 | 2024 | 396112 | 0.150 |
Why?
|
Cadherins | 1 | 2023 | 900 | 0.150 |
Why?
|
Postoperative Complications | 6 | 2024 | 15747 | 0.150 |
Why?
|
Epithelial-Mesenchymal Transition | 1 | 2023 | 752 | 0.150 |
Why?
|
Gastroparesis | 1 | 2020 | 143 | 0.150 |
Why?
|
Aged, 80 and over | 10 | 2024 | 59489 | 0.150 |
Why?
|
Aortic Diseases | 1 | 2024 | 729 | 0.150 |
Why?
|
C-Reactive Protein | 4 | 2023 | 3850 | 0.140 |
Why?
|
Fibrosis | 1 | 2024 | 2070 | 0.140 |
Why?
|
Aorta, Thoracic | 1 | 2024 | 1103 | 0.140 |
Why?
|
beta Catenin | 1 | 2022 | 1043 | 0.140 |
Why?
|
Multicenter Studies as Topic | 1 | 2022 | 1731 | 0.140 |
Why?
|
Inflammation | 5 | 2023 | 10850 | 0.130 |
Why?
|
Pancreatic Neoplasms | 1 | 2014 | 5444 | 0.130 |
Why?
|
Stomach | 1 | 2021 | 699 | 0.130 |
Why?
|
Heat-Shock Response | 1 | 2017 | 179 | 0.130 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2021 | 2024 | 0.130 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2020 | 8611 | 0.130 |
Why?
|
Drug Monitoring | 1 | 2022 | 962 | 0.120 |
Why?
|
Transforming Growth Factor beta | 1 | 2023 | 1995 | 0.120 |
Why?
|
Gastrins | 1 | 2015 | 75 | 0.120 |
Why?
|
Drug Combinations | 1 | 2021 | 2077 | 0.120 |
Why?
|
Rectal Neoplasms | 1 | 2024 | 1182 | 0.120 |
Why?
|
Sarcopenia | 1 | 2020 | 378 | 0.120 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2022 | 1242 | 0.120 |
Why?
|
Neoplasms, Complex and Mixed | 1 | 2015 | 35 | 0.120 |
Why?
|
Neoplasm Invasiveness | 3 | 2021 | 3602 | 0.110 |
Why?
|
Disease Progression | 5 | 2021 | 13632 | 0.110 |
Why?
|
Japan | 3 | 2024 | 1415 | 0.100 |
Why?
|
Radiopharmaceuticals | 1 | 2002 | 2699 | 0.100 |
Why?
|
Splenectomy | 1 | 2014 | 390 | 0.100 |
Why?
|
Combined Modality Therapy | 1 | 2024 | 8529 | 0.100 |
Why?
|
Adenocarcinoma | 2 | 2023 | 6364 | 0.100 |
Why?
|
Up-Regulation | 1 | 2021 | 4137 | 0.100 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2018 | 616 | 0.100 |
Why?
|
Follow-Up Studies | 3 | 2024 | 39193 | 0.100 |
Why?
|
Esophagogastric Junction | 2 | 2024 | 351 | 0.090 |
Why?
|
Nutritional Status | 1 | 2020 | 1620 | 0.090 |
Why?
|
Inflammation Mediators | 1 | 2020 | 1884 | 0.090 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2015 | 341 | 0.090 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2020 | 1892 | 0.090 |
Why?
|
Hepatectomy | 1 | 2014 | 589 | 0.090 |
Why?
|
Obesity, Morbid | 1 | 2021 | 1292 | 0.090 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2018 | 961 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2014 | 1831 | 0.080 |
Why?
|
Comorbidity | 1 | 2024 | 10563 | 0.080 |
Why?
|
Immunohistochemistry | 1 | 2021 | 11022 | 0.070 |
Why?
|
Endoscopy, Gastrointestinal | 1 | 2014 | 888 | 0.070 |
Why?
|
Protein Binding | 1 | 2019 | 9296 | 0.070 |
Why?
|
Adult | 8 | 2024 | 223044 | 0.070 |
Why?
|
Intestines | 1 | 2015 | 1906 | 0.060 |
Why?
|
Prospective Studies | 2 | 2021 | 54802 | 0.060 |
Why?
|
Positron-Emission Tomography | 1 | 2021 | 6547 | 0.060 |
Why?
|
Carrier Proteins | 1 | 2017 | 4913 | 0.060 |
Why?
|
Surgical Stapling | 1 | 2024 | 99 | 0.050 |
Why?
|
Survival Analysis | 3 | 2021 | 10070 | 0.050 |
Why?
|
Neoplasm Staging | 3 | 2024 | 11206 | 0.050 |
Why?
|
Treatment Outcome | 7 | 2024 | 65188 | 0.050 |
Why?
|
Risk Factors | 4 | 2024 | 74840 | 0.050 |
Why?
|
Nephelometry and Turbidimetry | 1 | 2002 | 91 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2020 | 9601 | 0.050 |
Why?
|
Sodium Fluoride | 1 | 2002 | 60 | 0.050 |
Why?
|
Pleura | 1 | 2024 | 240 | 0.050 |
Why?
|
Colony-Stimulating Factors | 1 | 2022 | 218 | 0.050 |
Why?
|
Periodontal Pocket | 1 | 2022 | 174 | 0.050 |
Why?
|
Oral Hygiene | 1 | 2022 | 132 | 0.050 |
Why?
|
Protein Kinase Inhibitors | 1 | 2018 | 5696 | 0.050 |
Why?
|
Injections, Intraperitoneal | 1 | 2022 | 413 | 0.050 |
Why?
|
Duodenum | 1 | 2024 | 495 | 0.050 |
Why?
|
Anastomosis, Surgical | 1 | 2024 | 990 | 0.040 |
Why?
|
Taxoids | 1 | 2023 | 665 | 0.040 |
Why?
|
Kaplan-Meier Estimate | 2 | 2021 | 6499 | 0.040 |
Why?
|
Electrocoagulation | 1 | 2020 | 157 | 0.040 |
Why?
|
Quality Control | 1 | 2002 | 837 | 0.040 |
Why?
|
Antigens, Differentiation, Myelomonocytic | 1 | 2020 | 281 | 0.040 |
Why?
|
Preoperative Period | 1 | 2021 | 566 | 0.040 |
Why?
|
Intra-Abdominal Fat | 1 | 2023 | 623 | 0.040 |
Why?
|
Antineoplastic Agents | 2 | 2018 | 13648 | 0.040 |
Why?
|
Hydrogen-Ion Concentration | 1 | 2002 | 2477 | 0.040 |
Why?
|
Lymph Node Excision | 1 | 2024 | 1259 | 0.040 |
Why?
|
Lymphocyte Count | 1 | 2020 | 790 | 0.040 |
Why?
|
Body Temperature | 1 | 2021 | 779 | 0.040 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2021 | 12240 | 0.030 |
Why?
|
Cytotoxins | 1 | 2017 | 154 | 0.030 |
Why?
|
Collagen | 1 | 2024 | 2618 | 0.030 |
Why?
|
Glycosylation | 1 | 2019 | 1100 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 2 | 2022 | 20659 | 0.030 |
Why?
|
Active Transport, Cell Nucleus | 1 | 2017 | 431 | 0.030 |
Why?
|
Sirolimus | 1 | 2023 | 1545 | 0.030 |
Why?
|
Abdomen | 1 | 2022 | 1134 | 0.030 |
Why?
|
Clinical Trials, Phase II as Topic | 1 | 2018 | 639 | 0.030 |
Why?
|
HSP70 Heat-Shock Proteins | 1 | 2017 | 393 | 0.030 |
Why?
|
Cell Communication | 1 | 2022 | 1660 | 0.030 |
Why?
|
Consciousness | 1 | 2020 | 601 | 0.030 |
Why?
|
Radiotherapy, Intensity-Modulated | 1 | 2021 | 784 | 0.030 |
Why?
|
Body Composition | 1 | 2024 | 2439 | 0.030 |
Why?
|
Salvage Therapy | 1 | 2021 | 1272 | 0.030 |
Why?
|
Metaplasia | 1 | 2015 | 326 | 0.030 |
Why?
|
Drug Therapy, Combination | 1 | 2024 | 6309 | 0.030 |
Why?
|
Long-Term Care | 1 | 2018 | 629 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2018 | 878 | 0.030 |
Why?
|
Chest Pain | 1 | 2020 | 1100 | 0.030 |
Why?
|
Neoplasms | 1 | 2022 | 22340 | 0.030 |
Why?
|
Lymph Nodes | 1 | 2024 | 3454 | 0.030 |
Why?
|
Animals | 2 | 2021 | 168764 | 0.020 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 17075 | 0.020 |
Why?
|
Receptors, Cell Surface | 1 | 2020 | 2817 | 0.020 |
Why?
|
Neoplasm Metastasis | 1 | 2022 | 4893 | 0.020 |
Why?
|
Radiography | 1 | 2022 | 6919 | 0.020 |
Why?
|
Blood Platelets | 1 | 2021 | 2464 | 0.020 |
Why?
|
Antigens, CD | 1 | 2020 | 4025 | 0.020 |
Why?
|
Tumor Microenvironment | 1 | 2022 | 3946 | 0.020 |
Why?
|
Cell Nucleus | 1 | 2017 | 2867 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2017 | 3421 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2021 | 12056 | 0.020 |
Why?
|
Cell Survival | 1 | 2017 | 5747 | 0.020 |
Why?
|
Age Factors | 1 | 2024 | 18380 | 0.020 |
Why?
|
Liver | 1 | 2021 | 7562 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2022 | 7478 | 0.010 |
Why?
|
Immunotherapy | 1 | 2019 | 4752 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2017 | 10429 | 0.010 |
Why?
|
Obesity | 1 | 2021 | 13076 | 0.010 |
Why?
|
Time Factors | 1 | 2018 | 40065 | 0.010 |
Why?
|